Good and Prolonged Response to Low Dose Capecitabine as Second Line Therapy in a Patient with Advanced Hepatocellular CarcinomaCaterina Soldà1*, Giuseppe Lombardi2, Camillo Aliberti3, Silvano Fasolato4, Paolo Angeli4, Davide Pastorelli1
- *Corresponding Author:
- Caterina Soldà
Rare Tumors Unit, Veneto Institute of Oncology– IRCCS. Italy
Email: [email protected]
Received Date: August 22, 2015 Accepted Date: December 18, 2015 Published Date: December 23, 2015
Citation: Soldà C, Lombardi G, Aliberti C, Fasolato S,Angeli P, Pastorelli D (2015) Good and Prolonged Response to Low Dose Capecitabine as Second Line Therapy in a Patient with Advanced Hepatocellular Carcinoma. Chemo Open Access 5:181. doi: 10.4172/2167-7700.1000181
Copyright: © 2015 Soldà, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Sorafenib is the only validated pharmacological treatment option for patients with advanced hepatocellular carcinoma (HCC) in the context of Child-Pugh class A liver function. Effective and safe systemic treatments for advanced disease with severe underlying cirrhosis (Child-Pugh class B and C) are not yet available. A few reports have described capecitabine as an option after failure of sorafenib or for patients who were not eligible for clinical trials. Here, we present a case of good response to low dose capecitabine in a patient with advanced HCC.